Roivant Sciences : View Presentation

Oncology Overview

January 2022

Forward-Looking Statements

Forward-Looking Statements and Disclaimer

This presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the sections captioned "Risk Factors" and "Forward-Looking Statements" of our filings with the U.S. Securities and Exchange Commission, available at www.sec.gov and investor.roivant.com. We operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

2

Roivant: Redefining "Big Pharma" from End to End

We are a biopharmaceutical company discovering, developing and commercializing transformative medicines faster by building technologies and deploying talent in creative ways

Vant Model

Computational Tools

Aligning incentives to promote successful execution, with Vants

benefiting from support of the Roivant platform

Immunovant

DermavantAruvant

Genevant	Datavant	New Vants from
Lysovant
Kinevant
Proteovant		New Vants from
	Additional
Hemavant		In-Licensing
Alyvant	Lokavant

Priovant	Affivant
Sio Cytovant	Arbutus

Technologies built to address inefficiencies in drug discovery,

development and commercialization processes

Indicates Vant or strategy with oncology relevance

3

Note: Vants shown include non-wholly-owned subsidiaries and affiliates of Roivant. For more information on Roivant's ownership in the Vants, please see the Vant ownership table in the "Overview" Section of Part I, Item 2 of Roivant's most recent Form 10-Q filed with the U.S. Securities and Exchange Commission, and available at www.sec.govand investor.roivant.com.

Select Discovery and Development Pipeline in Oncology to Address Unmet Patient Needs

					Modality	Discovery Preclinical Phase 1/2
				RVT-2001	Transfusion-Dependent Anemia in Patients with Lower-Risk MDS	►
				AFM32	Solid Tumors	►
				CVT-TCR-01	Oncologic Malignancies	►
				AR	Prostate Cancer	►
				STAT3	Oncology, Immunology	►
				Undisclosed	Oncology	►
				CBP/p300	Oncology	►
				SMARCA2/4	Oncology	►
				Undisclosed	Oncology	►
				Multiple Additional Targets	Oncology, Immunology	►
				WRN	Oncology	►
				CRAF	Oncology	►
				HIF2A	Oncology	►
				ADAR1	Oncology	►
				Multiple Additional Targets	Oncology, Immunology, Neurology	►
				KRAS G12D	Oncology	►

Note: All drugs in current pipeline are investigational and subject to health authority approval.						4
			Roivant		Inhibitor/
Cytovant Hemavant	Affivant	Proteovant	Degrader	Biologic
Discovery	Modulator

RVT-2001: Potential First-in-Class Small Molecule SF3B1 Modulator for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Lower-Risk MDS	Encouraging	Multipronged	Expect Fast,
Strategy to	Well-Established	Strong Intellectual
is a Commercially	Proof-of-Concept
Optimize RVT-2001's	Path to Potential	Property Position
Validated Market	Data
Clinical Impact	Approval

Transfusion-dependent anemia in MDS has limited treatment options

Luspatercept (Reblozyl), approved for RS+ MDS in 2020, annualizing at >$500M 5 quarters after launch; BMS potential projected peak >$4B1

First-in-class potential as	Planned development	Intend to conduct a
the only known SF3B1	strategy optimizing	robust open-label
modulator currently in	dosing, utilizing precision	expansion of an ongoing
clinical development	medicine enrollment, and	Phase 1/2 trial in 2022
	excluding certain
Compelling data in a	refractory patients	Precedent in the space is
highly refractory		a single pivotal study with
population	Precedent suggests	approximately 200-250
	minimal data decay	patients4
80+ subjects treated in	between Phase 2 and
Phase 1/2 study;	Phase 33
generally well-tolerated to
date2

Composition of matter IP protection expected until 2035, before any potential patent term extensions

All product candidates are investigational and subject to regulatory approval.	5
1.	Bristol Myers Squibb filings, November 16, 2021 Investor Event.
2.	Steensma et al., 2021
3.	Platzbecker et al., 2017; Fenaux et al., 2020; List et al., 2006; Fenaux et al., 2011
4.	Fenaux et al., 2021; Fenaux et al. 2011; Santini et al. 2016